Different sensitivities of senescent breast cancer cells to immune cell-mediated cytotoxicity.
Aminopyridines
/ pharmacology
Antibody-Dependent Cell Cytotoxicity
/ drug effects
Antineoplastic Combined Chemotherapy Protocols
/ pharmacology
Apoptosis
/ drug effects
Apoptosis Regulatory Proteins
/ immunology
Benzimidazoles
/ pharmacology
Breast Neoplasms
/ drug therapy
CD4-Positive T-Lymphocytes
/ drug effects
Cell Line, Tumor
Cellular Senescence
/ drug effects
Cyclin-Dependent Kinase 4
/ antagonists & inhibitors
Cyclin-Dependent Kinase 6
/ antagonists & inhibitors
Doxorubicin
/ pharmacology
Drug Screening Assays, Antitumor
Female
Humans
Killer Cells, Natural
/ drug effects
Molecular Targeted Therapy
/ methods
Neoplasm Recurrence, Local
abemaciclib
breast cancer
cytotoxicity
doxorubicin
senescence
Journal
Cancer science
ISSN: 1349-7006
Titre abrégé: Cancer Sci
Pays: England
ID NLM: 101168776
Informations de publication
Date de publication:
Sep 2019
Sep 2019
Historique:
received:
15
04
2019
revised:
22
06
2019
accepted:
25
06
2019
pubmed:
30
6
2019
medline:
1
10
2019
entrez:
29
6
2019
Statut:
ppublish
Résumé
Senescence is a state of growth arrest induced not only in normal cells but also in cancer cells by aging or stress, which triggers DNA damage. Despite growth suppression, senescent cancer cells promote tumor formation and recurrence by producing cytokines and growth factors; this state is designated as the senescence-associated secretory phenotype. In this study, we examined the susceptibility of senescent human breast cancer cells to immune cell-mediated cytotoxicity. Doxorubicin (DXR) treatment induced senescence in 2 human breast cancer cell lines, MDA-MB-231 and BT-549, with the induction of γH2AX expression and increased expression of p21 or p16. Treatment with DXR also induced the expression of senescence-associated β-galactosidase and promoted the production of pro-inflammatory cytokines. Importantly, DXR-treated senescent MDA-MB-231 cells showed increased sensitivity to 2 types of immune cell-mediated cytotoxicity: cytotoxicity of activated CD4
Identifiants
pubmed: 31250942
doi: 10.1111/cas.14116
pmc: PMC6726686
doi:
Substances chimiques
Aminopyridines
0
Apoptosis Regulatory Proteins
0
Benzimidazoles
0
abemaciclib
60UAB198HK
Doxorubicin
80168379AG
CDK4 protein, human
EC 2.7.11.22
CDK6 protein, human
EC 2.7.11.22
Cyclin-Dependent Kinase 4
EC 2.7.11.22
Cyclin-Dependent Kinase 6
EC 2.7.11.22
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2690-2699Subventions
Organisme : Japan Society for the Promotion of Science KAKENHI
ID : 17K07217
Organisme : Shimane University "SUIGANN" Project
Informations de copyright
© 2019 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association.
Références
N Engl J Med. 2017 Nov 16;377(20):1919-1929
pubmed: 28885881
J Pharm Pharmacol. 2013 Feb;65(2):157-70
pubmed: 23278683
Cell Commun Signal. 2017 May 4;15(1):17
pubmed: 28472950
N Engl J Med. 2018 Nov 22;379(21):2040-2051
pubmed: 30280635
PLoS One. 2017 Feb 24;12(2):e0172832
pubmed: 28235006
J Clin Oncol. 2015 Jun 10;33(17):1974-82
pubmed: 25605845
Breast Cancer Res Treat. 2000 Aug;62(3):223-35
pubmed: 11072787
Clin Cancer Res. 2005 Sep 15;11(18):6713-21
pubmed: 16166452
Oncogene. 2005 Apr 18;24(17):2899-908
pubmed: 15838523
Cell. 2008 Jun 13;133(6):1019-31
pubmed: 18555778
Cell. 2008 Jun 13;133(6):1006-18
pubmed: 18555777
Exp Gerontol. 2000 May;35(3):317-29
pubmed: 10832053
Cancer Sci. 2019 Sep;110(9):2690-2699
pubmed: 31250942
Oncoimmunology. 2014 Aug 03;3(8):e954471
pubmed: 25610747
Nat Med. 2001 Jan;7(1):94-100
pubmed: 11135622
Cancer Res. 2008 Apr 1;68(7):2062-4
pubmed: 18381408
Cancer Cell. 2018 Jul 9;34(1):9-20
pubmed: 29731395
Oncologist. 2015 May;20(5):483-90
pubmed: 25876993
Annu Rev Pathol. 2010;5:99-118
pubmed: 20078217
South Med J. 2017 Oct;110(10):638-642
pubmed: 28973704
PLoS Biol. 2008 Dec 2;6(12):2853-68
pubmed: 19053174
Annu Rev Immunol. 2013;31:51-72
pubmed: 23157435
Cancer Sci. 2017 Apr;108(4):563-569
pubmed: 28165648
Biogerontology. 2016 Feb;17(1):71-87
pubmed: 26330289
J Immunol. 1996 May 15;156(10):3678-86
pubmed: 8621902
Clin Cancer Res. 2019 Feb 1;25(3):921-927
pubmed: 30287548
Br J Cancer. 2003 Jun 2;88(11):1721-6
pubmed: 12771987
Breast Cancer Res. 2007;9(1):R15
pubmed: 17261184
Cancer Discov. 2018 Feb;8(2):216-233
pubmed: 29101163
J Natl Cancer Inst. 2010 Oct 20;102(20):1536-46
pubmed: 20858887
Ann Oncol. 2013 Nov;24(11):2801-7
pubmed: 23908177
Nature. 2017 Aug 24;548(7668):471-475
pubmed: 28813415
Lancet Oncol. 2016 Apr;17(4):425-439
pubmed: 26947331
J Biol Chem. 2004 Aug 27;279(35):36916-22
pubmed: 15210716
Annu Rev Physiol. 2013;75:685-705
pubmed: 23140366
Cell Rep. 2018 Mar 13;22(11):2978-2994
pubmed: 29539425
Breast Cancer Res. 2010;12(4):R49
pubmed: 20630060
Cancer Res. 2013 Jun 1;73(11):3470-80
pubmed: 23633491
JAMA Oncol. 2017 Apr 1;3(4):524-548
pubmed: 27918777
Eur J Immunol. 2004 Feb;34(2):336-44
pubmed: 14768038
Cancer Res. 2015 Dec 1;75(23):5034-45
pubmed: 26573793